合成肽 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
A strain field associated with a displacement is defined, at any point, by the change in length of the tangent vectors representing the speeds of arbitrarily parametrized curves passing through that point. A basic geometric result, due to Fréchet, von Neumann and Jordan, states that, if the lengths of the tangent vectors fulfil the axioms of a norm and the parallelogram law, then the length of a vector is the square root of the value of the quadratic form associated, by the polarization formula, with a positive definite bilinear form called the metric tensor.
It is believed that the first documented European to explore the east coast of Canada was Norse explorer Leif Erikson. In approximately 1000 AD, the Norse built a small short-lived encampment that was occupied sporadically for perhaps 20 years at L'Anse aux Meadows on the northern tip of Newfoundland. No further European exploration occurred until 1497, when seafarer John Cabot explored and claimed Canada's Atlantic coast in the name of Henry VII of England. In 1534, French explorer Jacques Cartier explored the Gulf of Saint Lawrence where, on July 24, he planted a 10-metre (33 ft) cross bearing the words, "long live the King of France", and took possession of the territory New France in the name of King Francis I. The early 16th century saw European mariners with navigational techniques pioneered by the Basque and Portuguese establish seasonal whaling and fishing outposts along the Atlantic coast. In general, early settlements appear to have been short-lived due to a combination of the harsh climate, problems with navigating trade routes and competing outputs in Scandinavia. In 1583, Sir Humphrey Gilbert, by the royal prerogative of Queen Elizabeth I, founded St John's, Newfoundland, as the first North American English seasonal camp. In 1600, the French established their first seasonal trading post at Tadoussac along the Saint Lawrence. French explorer Samuel de Champlain arrived in 1603 and established the first permanent year-round European settlements at Port Royal (in 1605) and Quebec City (in 1608).
=== Pediatric drug testing === Prior to the 1990s, only 20% of all drugs prescribed for children in the United States were tested for safety or efficacy in a pediatric population. This became a major concern of pediatricians as evidence accumulated that the physiological response of children to many drugs differed significantly from those drugs' effects on adults. Children react differently to the drugs because of many reasons, including size, weight, etc. There were several reasons that few medical trials were done with children. For many drugs, children represented such a small proportion of the potential market, that drug manufacturers did not see such testing as cost-effective. Also, the belief that children are ethically restricted in their ability to give informed consent brought increased governmental and institutional hurdles to approval of these clinical trials, and greater concerns about legal liability. Thus, for decades, most medicines prescribed to children in the U.S. were done so in a non-FDA-approved, "off-label" manner, with dosages "extrapolated" from adult data through body weight and body-surface-area calculations. In an initial FDA attempt to address this issue they produced the 1994 FDA Final Rule on Pediatric Labeling and Extrapolation, which allowed manufacturers to add pediatric labeling information, but required drugs that had not been tested for pediatric safety and efficacy to bear a disclaimer to that effect. However, this rule failed to motivate many drug companies to conduct additional pediatric drug trials.
=== Synthetic Yeast 2.0 === As part of the Synthetic Yeast 2.0 project, various research groups around the world have participated in a project to synthesise synthetic yeast genomes, and through this process, optimise the genome of the model organism Saccharomyces cerevisiae. The Yeast 2.0 project applied various DNA assembly methods that have been discussed above, and in March 2014, Jef Boeke of the Langone Medical Centre at New York University, revealed that his team had synthesized chromosome III of S. cerevisiae. The procedure involved replacing the genes in the original chromosome with synthetic versions and the finished synthetic chromosome was then integrated into a yeast cell. It required designing and creating 273,871 base pairs of DNA – fewer than the 316,667 pairs in the original chromosome. In March 2017, the synthesis of 6 of the 16 chromosomes had been completed, with synthesis of the others still ongoing.
Sources: en.wikipedia.org
Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. The conjugate is abbreviated T-DM1. In the EMILIA clinical trial of women with advanced HER2 positive breast cancer who were already resistant to trastuzumab alone, it improved median overall survival by 5.8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration (FDA) approved marketing on 22 February 2013. Trastuzumab emtansine was developed by Genentech, and is manufactured by Lonza.
=== Machine Learning applications === Machine learning models trained on these molecular representations have been applied to predict various chirality-related properties. One practical application is forecasting the elution order of enantiomers in chiral chromatography. Models trained on experimental retention data from chiral stationary phases can learn structure-retention relationships. Random Forest and other ensemble methods have been applied to predict which enantiomer elutes first on columns such as Chiralpak AD-H using both traditional circular fingerprints and neural network-derived descriptors. Another application is the prediction of optical rotation, a fundamental chiral property. Machine learning models have been developed to predict specific rotation values for chiral molecules based on their structure, with applications to both organic compounds and specialized classes such as chiral fluorinated molecules. These predictions can assist in structural characterization and quality control in pharmaceutical development. While these machine learning approaches show promise, several limitations remain. Model accuracy depends heavily on training data quality and coverage of chemical space. Neural network architectures, particularly Transformers, face inherent challenges in learning stereochemical features from string-based representations like SMILES.
"Like typical metals, it [astatine] is precipitated by hydrogen sulfide even from strongly acid solutions and is displaced in a free form from sulfate solutions; it is deposited on the cathode on electrolysis." Further indications of a tendency for astatine to behave like a (heavy) metal are: "... the formation of pseudohalide compounds ... complexes of astatine cations ... complex anions of trivalent astatine ... as well as complexes with a variety of organic solvents". It has also been argued that astatine demonstrates cationic behaviour, by way of stable At+ and AtO+ forms, in strongly acidic aqueous solutions. Some of astatine's reported properties are nonmetallic. It has been extrapolated to have the narrow liquid range ordinarily associated with nonmetals (mp 302 °C; bp 337 °C), although experimental indications suggest a lower boiling point of about 230±3 °C. Batsanov gives a calculated band gap energy for astatine of 0.7 eV; this is consistent with nonmetals (in physics) having separated valence and conduction bands and thereby being either semiconductors or insulators. The chemistry of astatine in aqueous solution is mainly characterised by the formation of various anionic species. Most of its known compounds resemble those of iodine, which is a halogen and a nonmetal. Such compounds include astatides (XAt), astatates (XAtO3), and monovalent interhalogen compounds. Restrepo et al. reported that astatine appeared to be more polonium-like than halogen-like.
=== Greater Western Sydney === On 17 May 2022, it was announced that Hird would be joining the coaching staff at Greater Western Sydney as part-time assistant coach for the rest of the 2022 season under GWS caretaker senior coach and his former teammate Mark McVeigh, who replaced Leon Cameron after he resigned as the club's senior coach midway through the season. On 2 February 2023, Hird departed the club.
The overwhelming majority of MRONJ diagnoses, however, were associated with intravenous administration of bisphosphonates (94%). Only the remaining 6% of cases arose in patients taking bisphosphonates orally. Although the total United States prescriptions for oral bisphosphonates exceeded 30 million in 2006, less than 10% of MRONJ cases were associated with patients taking oral bisphosphonate drugs. Studies have estimated that BRONJ occurs in roughly 20% of patients taking intravenous zoledronic acid for cancer therapy and in between 0–0.04% of patients taking orally administered bisphosphonates. Owing to prolonged embedding of bisphosphonate drugs in the bone tissues, the risk for MRONJ is elevated even after stopping the administration of the medication for several years. Patients who stopped taking anti-angiogenic drugs are exposed to the same risk as patients who have never taken the drugs because anti-angiogenic drugs do not normally reside in the body for a long period of time. Risk factors include:
Sources: en.wikipedia.org
Haemovigilance – incident management, investigation, follow-up, and reporting Risk management including writing, implementing, updating and monitoring local policies and procedures Blood management education Monitoring and providing feedback on activities related to compliance with best practice guidelines including auditing Change management activities Appropriate use and management including waste minimisation Assisting with the implementation of PBM strategies
In the 20th century, World War II, the space race and the rising consumer society in developed countries contributed to the growth of food processing with such advances as spray drying, evaporation, juice concentrates, freeze drying and the introduction of artificial sweeteners, colouring agents, and such preservatives as sodium benzoate. In the late 20th century, products such as dried instant soups, reconstituted fruits and juices, and self cooking meals such as MRE food ration were developed. By the 20th century, automatic appliances like microwave oven, blender, and rotimatic paved way for convenience cooking. In western Europe and North America, the second half of the 20th century witnessed a rise in the pursuit of convenience. Food processing companies marketed their products especially towards middle-class working wives and mothers. Frozen foods (often credited to Clarence Birdseye) found their success in sales of juice concentrates and "TV dinners". Processors utilised the perceived value of time to appeal to the postwar population, and this same appeal contributes to the success of convenience foods today. Also in the late 20th century, food manufacturers began changing their product model from a single "platonic dish", such as one version of jarred spaghetti sauce, to offering multiple variations, such as a plain version, a spicy version, and a chunky version.
=== EC 2.7.2: Phosphotransferases with a carboxy group as acceptor === EC 2.7.2.1: acetate kinase EC 2.7.2.2: carbamate kinase EC 2.7.2.3: phosphoglycerate kinase EC 2.7.2.4: aspartate kinase EC 2.7.2.5: Now EC 6.3.4.16, carbamoyl-phosphate synthase (ammonia) EC 2.7.2.6: formate kinase EC 2.7.2.7: butyrate kinase EC 2.7.2.8: acetylglutamate kinase EC 2.7.2.9: Now EC 6.3.5.5, carbamoyl-phosphate synthase (glutamine-hydrolysing) EC 2.7.2.10: phosphoglycerate kinase (GTP) EC 2.7.2.11: glutamate 5-kinase EC 2.7.2.12: acetate kinase (diphosphate) EC 2.7.2.13: Now known to be due to the activities of EC 6.1.1.17, glutamate—tRNA ligase, EC 1.2.1.70, glutamyl-tRNA reductase and EC 5.4.3.8 glutamate-1-semialdehyde 2,1-aminomutase EC 2.7.2.14: branched-chain-fatty-acid kinase EC 2.7.2.15: propionate kinase EC 2.7.2.16: 2-phosphoglycerate kinase EC 2.7.2.17: [amino-group carrier protein]-L-2-aminoadipate 6-kinase EC 2.7.2.18: fatty acid kinase
Biomedical Sciences Molecular and Cellular Biology Bioengineering and Devices Biophysics, Biochemistry and Structural Biology Climate science, Agriculture and Environment Biotechnology Regulatory Affairs, IPR and Policy
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.